BUPRENEX Drug Patent Profile
✉ Email this page to a colleague
When do Buprenex patents expire, and when can generic versions of Buprenex launch?
Buprenex is a drug marketed by Indivior and is included in one NDA.
The generic ingredient in BUPRENEX is buprenorphine hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Buprenex
A generic version of BUPRENEX was approved as buprenorphine hydrochloride by HOSPIRA on June 3rd, 1996.
Summary for BUPRENEX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 18 |
Clinical Trials: | 8 |
Patent Applications: | 5,370 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for BUPRENEX |
What excipients (inactive ingredients) are in BUPRENEX? | BUPRENEX excipients list |
DailyMed Link: | BUPRENEX at DailyMed |
Recent Clinical Trials for BUPRENEX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Medical College of Wisconsin | Phase 2 |
United States Department of Defense | Phase 1/Phase 2 |
Yale University | Phase 1/Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for BUPRENEX
US Patents and Regulatory Information for BUPRENEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Indivior | BUPRENEX | buprenorphine hydrochloride | INJECTABLE;INJECTION | 018401-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |